Add to ORKGObjective. To determine the pattern of demyelinating disorders (DDs) occurring during anti-TNF-a therapy. Methods. Between June 2005 and April 2008, 1800 French rheumatologists and internists were contacted to report cases of DDs occurring in patients treated with anti-TNF-a. Results. After a median of 10.2 (1.539.9) months of treatment, 33 patients developed DDs: 22 had CNS and 11 peripheral nervous system (PNS) involvement. Underlying diseases were RA (n = 16), AS (n = 11)
Tumor necrosis factor alpha (TNF-α) is a pro-inflammatory and immunoregulatory cytokine involved in ...
Objective: To assess anti-tumour necrosis factor (anti-TNF) agents in patients with refractory syste...
International audienceBACKGROUND: TNFα blockers have drastically improved rheumatoid arthritis progn...
Objective. To determine the pattern of demyelinating disorders (DDs) occurring during anti-TNF-a the...
Copyright © 2013 E. Andreadou et al. This is an open access article distributed under the Creative C...
Previous studies have reported an association between anti-tumor necrosis factor alpha (anti-TNFα) t...
Background: Anti-TNF exposure has been linked to demyelination events. We sought to describe the cli...
Introduction Tumor necrosis factor- (TNF) blockers are efficient in the treatment of autoimmune diso...
Background: Anti-TNF exposure has been linked to demyelination events. We sought to describe the cli...
There are few case reports documenting a new onset of demyelinating processes in patients receiving ...
Tumor necrosis factor (TNF)-targeted therapies are increasingly used for a rapidly expanding number ...
The use of Tumor Necrosis Factor alpha (TNF--α) antagonists has profoundly improved clinical managem...
Summary: A case of multiple sclerosis presenting during anti–tumor necrosis factor treatment for rhe...
: Antagonists of tumour necrosis factor α (TNFα) are a common therapeutic choice for autoimmune dise...
Infliximab, a monoclonal anti-TNF α antibody prescribed for treatment of inflammatory and autoimmune...
Tumor necrosis factor alpha (TNF-α) is a pro-inflammatory and immunoregulatory cytokine involved in ...
Objective: To assess anti-tumour necrosis factor (anti-TNF) agents in patients with refractory syste...
International audienceBACKGROUND: TNFα blockers have drastically improved rheumatoid arthritis progn...
Objective. To determine the pattern of demyelinating disorders (DDs) occurring during anti-TNF-a the...
Copyright © 2013 E. Andreadou et al. This is an open access article distributed under the Creative C...
Previous studies have reported an association between anti-tumor necrosis factor alpha (anti-TNFα) t...
Background: Anti-TNF exposure has been linked to demyelination events. We sought to describe the cli...
Introduction Tumor necrosis factor- (TNF) blockers are efficient in the treatment of autoimmune diso...
Background: Anti-TNF exposure has been linked to demyelination events. We sought to describe the cli...
There are few case reports documenting a new onset of demyelinating processes in patients receiving ...
Tumor necrosis factor (TNF)-targeted therapies are increasingly used for a rapidly expanding number ...
The use of Tumor Necrosis Factor alpha (TNF--α) antagonists has profoundly improved clinical managem...
Summary: A case of multiple sclerosis presenting during anti–tumor necrosis factor treatment for rhe...
: Antagonists of tumour necrosis factor α (TNFα) are a common therapeutic choice for autoimmune dise...
Infliximab, a monoclonal anti-TNF α antibody prescribed for treatment of inflammatory and autoimmune...
Tumor necrosis factor alpha (TNF-α) is a pro-inflammatory and immunoregulatory cytokine involved in ...
Objective: To assess anti-tumour necrosis factor (anti-TNF) agents in patients with refractory syste...
International audienceBACKGROUND: TNFα blockers have drastically improved rheumatoid arthritis progn...